Oxford Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Oxford Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+12,095	New	+$229K	0.11%	296
2025 Q2	–	Sell	-8,962	Closed	-$572K	–	749
2025 Q1	$572K	Buy	+8,962	New	+$943K	0.26%	106
2024 Q3	–	Sell	-1,865	Closed	-$295K	–	438
2024 Q2	$295K	Buy	+1,865	New	+$240K	0.29%	134
2016 Q2	–	Sell	-187,149	Closed	-$3.65M	–	870
2016 Q1	$3.65M	Buy	187,149 +84,883	+83%	+$1.48M	0.1%	246
2015 Q4	$4.03M	Sell	102,266 -319,708	-76%	-$10.4M	0.1%	233
2015 Q3	$13.6M	Buy	421,974 +319,282	+311%	+$10.8M	0.43%	35
2015 Q2	$3.13M	Buy	+102,692	New	+$2.1M	0.08%	258
2014 Q2	–	Sell	-68,025	Closed	-$1.64M	–	770
2014 Q1	$1.64M	Sell	68,025 -42,053	-38%	-$1.07M	0.05%	399
2013 Q4	$2.24M	Sell	110,078 -430,389	-80%	-$12.8M	0.06%	397
2013 Q3	$25.5M	Buy	540,467 +252,057	+87%	+$9.71M	0.57%	13
2013 Q2	$11M	Buy	+288,410	New	+$10.3M	0.3%	71

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Oxford Asset Management's SRPT Position: Q2 2026 in Review

Oxford Asset Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 12,095 shares worth $217K. The stake represents 0.11% of the portfolio and ranks #296 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in SRPT as recently as Q1 2025.

Oxford Asset Management first reported a position in SRPT in Q2 2013 and has held it in 11 quarters since. The position peaked at $25.5M in Q3 2013. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Oxford Asset Management held 12,095 shares of Sarepta Therapeutics worth $217K as of Q2 2026.
Sarepta Therapeutics was a new Oxford Asset Management position in Q2 2026.
Sarepta Therapeutics made up 0.11% of Oxford Asset Management's portfolio in Q2 2026, its #296 holding.
Oxford Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 11 quarters since.
Oxford Asset Management's Sarepta Therapeutics position peaked at $25.5M in Q3 2013.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.